Patient
P2B-130
completed Phase IIA Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma · Blokhin Cancer Research Center (Moscow, Russia) (Dr. Moreau)
consented 2013-07-09
Adverse events
7
Serious AEs
1
Open data queries
3
Luna dropout signal
—
not on Luna
Adverse events 7
Grade 1 blood alkaline phosphatase increased with onset in cycle 6 (2013-12-05); assessed as not related to study drug (not related); resolved 2013-12-26.
Grade 3 abdominal pain with onset in cycle 6 (2013-11-26); assessed as not related to study drug (not related); resolved 2013-12-06; action: drug interrupted.
Grade 3 leukopenia with onset in cycle 5 (2013-11-02); assessed as related to study drug (probable); resolved 2013-11-09.
Grade 3 anaemia with onset in cycle 4 (2013-10-17); serious (hospitalization); assessed as related to study drug (probable); resolved 2013-11-10; action: drug interrupted.
Grade 2 anaemia with onset in cycle 3 (2013-09-09); assessed as related to study drug (probable); resolved 2013-10-08.
Grade 2 constipation with onset in cycle 2 (2013-08-19); assessed as not related to study drug (not related); resolved 2013-08-24.
Grade 1 nausea with onset in cycle 1 (2013-07-28); assessed as not related to study drug (not related); resolved 2013-07-29.
Data queries 3
Visit Cycle 6 Day 1: infusion (last planned cycle) (V7) for P2B-130 occurred on 2013-11-17, 9 d late against planned day 106 (2013-11-08 ± 3 d, anchored on first dose 2013-07-26). Confirm the visit date or record a protocol deviation.
Visit Cycle 5 Day 1: infusion; week-12 CT/MRI and ECHO/MUGA before dosing (V6) for P2B-130 occurred on 2013-10-26, 8 d late against planned day 85 (2013-10-18 ± 3 d, anchored on first dose 2013-07-26). Confirm the visit date or record a protocol deviation.
Visit Cycle 4 Day 1: infusion (V5) for P2B-130 occurred on 2013-10-05, 8 d late against planned day 64 (2013-09-27 ± 3 d, anchored on first dose 2013-07-26). Confirm the visit date or record a protocol deviation.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.